Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer

International Journal of Biological Markers

Volumn 15, Issue 2, 2000, Pages 161-164

  Bonfanti, A ^a   Lissoni, Paolo ^a   Bucovec, R ^a   Rovelli, F ^a   Brivio, F ^a   Fumagalli, L ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b CHIRON VACCINES   (Italy)

Author keywords

Angiogenesis; Dendritic cells; IL 12; IL 2; VEGF

Indexed keywords

GLYCOPROTEIN P 15095; RECOMBINANT INTERLEUKIN 12; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS;

EID: 0034122636     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500206     Document Type: Article

References (32)

1. Atzpodien J, Kirchner H. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990; 58: 1-11.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 42-6.
3. Bicknell R, Harris AL. Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 1991; 27: 781-6.
4. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180-91.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 1996; 86: 353-64.
6. Marincola FM. The multiple ways to tumor tolerance. J Immunother 1997; 20: 178-9.
7. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
8. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-103.
9. Leung DW, Cachianes C, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1990; 246: 1306-9.
10. Ferrara N, Houck KA, Jakeman LB, Winer L, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-8.
11. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821-6.
12. Salven P, Maenpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-51.
13. Savary CA, Grazziutti ML, Melichar B, et al. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 1998; 45: 234-40.
14. Lissoni P, Fumagalli L, Rovelli F, et al. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer 1998; 77: 1957-60.
15. Banks R, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71: 655-9.
16. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245-87.
17. Lissoni P, Fumagalli L, Giani L, et al. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations. Int J Biol Markers 1998; 13: 98-101.
18. Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189-97.
19. Lotze MT, Hellerstedt B, Stolinski L, et al. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am 1997; 3 (Suppl 1): S109-11.
20. Blay JY, Pallardy H, Ravaud A, et al. Serum VEGF is an independent prognostic factor in patients with metastatic renal carcinoma treated with IL-2 and/or IFN: analysis of the CRECY trial. Proc ASCO 1999; 18: 1669 (abstr).
21. Stadler W, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 1995; 22: 67-73.
22. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487-93.
23. Jones M, Philip T, Palmer P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993; 8: 275-81.
24. Capelli E, Nano R, Barni S. Dendritic cell differentiation in a peripheral blood mononucleated cell culture treated with interleukin-2. Haematologica 1997; 82: 634.
25. Puolakkainen P, Twardzik D, Ranchalis J, et al. Increase in plasma transforming growth factor beta (TGF-β) during immunotherapy with IL-2. Cancer Invest 1995; 13: 583-9.
26. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
27. Asham EH, Loizidou M, Taylor I. Endothelin-1 and tumour development. Eur J Surg Oncol 1998; 24: 57-60.
28. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-90.
29. Taniguchi K, Morimoto S, Fukuo K. Interleukin-2 suppresses endothelin-1 secretion of cultured endothelial cells. Hypertens Res 1992; 15: 171-5.
30. Shigematsu T, Miura S, Hirokawa M, et al. Induction of endothelin-1 synthesis by IL-2 and its modulation of rat intestinal epithelial cell growth. Am J Physiol 1998; 275: G556-63.
31. Honkoop A, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. The Oncologist 1999; 4: 106-11.
32. Shweiki D, Neeman M, Itin A, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.